الفهرس | Only 14 pages are availabe for public view |
Abstract Diabetic Ketoacidosis (DKA) is a potentially fatal metabolic disorder presenting as a common cause of intensive care unit admission. The disorder can have significant mortality if misdiagnosed or mistreated. The main features of DKA are hyperglycemia, metabolic acidosis with a high anion gap and heavy ketonuria. Insulin Glargin is along-acting basal insulin analogue shows no plasma insulin peaks. Insulin glargin was reported to be safe and effective to be added to the standard protocols of DKA management giving the advantage of reducing time of recovery of DKA patients and facilitate the transition from intravenous insulin infusion to subcutaneous injection, with no increase in risks of hypoglycemia, nor hypokalemia |